Stock Price & Analysis

Based on the recent data and market developments, here's my analysis for MDT stock:

Technical Analysis

The stock is currently trading around $83-84 range, showing some weakness in recent sessions. The RSI of 68.43 indicates the stock is approaching overbought territory but hasn't reached extreme levels yet.

Recent Events & Impact A significant development occurred on January 5, 2025, when Johnson & Johnson temporarily paused its Varipulse catheter launch due to safety concerns. This news is actually positive for Medtronic as it reduces competitive pressure in the cardiac ablation market.

Fundamental Analysis

The company maintains solid fundamentals:

• Revenue growth across all four businesses (cardiovascular, neuroscience, medical surgical, and diabetes)
• Particularly strong performance in the diabetes segment with 11% revenue growth
• The neuroscience division showed 6.7% growth, driven by adoption of spinal implants and neuromodulation products

Market Position & Growth Drivers

• Leading position in medical technology with over $30 billion in annual sales
• Strong growth potential in diabetes care market (38.4 million people in the U.S. have diabetes)
• Expanding neuroscience portfolio with innovative products like AiBLE and Percept

Recommendation SELL at current levels. While Medtronic has strong fundamentals and positive catalysts from reduced competition, the stock is approaching overbought territory and faces near-term resistance around $92-93. A better entry point may present itself if the stock pulls back to support levels around $82-83.

Based on the provided data and market context, here is the price prediction analysis for MDT stock in 2025:

MDT stock is expected to reach $95-98 by end of 2025, representing a potential upside of 8-11% from current levels around $88. This projection is supported by three key factors:

1. Strong growth in neuroscience and diabetes segments, with neuroscience revenue up 6.7% and diabetes revenue growing 11% in recent quarters. These high-growth segments will likely drive overall company performance.

2. Improved valuation metrics with P/E ratio of 25x, down from historical median of 30x over the past decade, suggesting room for multiple expansion as earnings growth accelerates.

3. Recent positive developments in pulsed field ablation (PFA) market after Johnson & Johnson's Varipulse pause, which creates opportunities for Medtronic to gain market share.

The stock has been consolidating between $82-93 range, with strong support at $82 and resistance at $92-93. A breakout above $93 could accelerate the move toward the price target.

The S1 support level for MDT Stock is $81.64 ,The R1 resistant level for MDT Stock is $89.5.

As of the end of day on 2025-01-24, the price of MDT Stock was $90.25.

The target price for MDT Stock according to analyst rating is 95.54, with the highest price target at 109.00 and the lowest at 87.00. Analysts have a Moderate Buy rating on MDT Stock overall.

The market cap of MDT is $115.6B.

Based on the provided data and market analysis, here is a concise evaluation of MDT's valuation:

MDT appears fairly valued at current levels based on several key metrics. The stock's P/E ratio of 27.65 in Q2 2025 is slightly below its 10-year median P/E of 30, suggesting reasonable valuation relative to historical levels.

Key Valuation Metrics:

• EV/EBITDA of 14.13 shows moderate valuation compared to medical device industry
• Price-to-Sales ratio of 3.60 indicates reasonable pricing for revenue generation
• Price-to-Book of 2.40 suggests the market is not overvaluing assets
• Healthy dividend yield of 3.07% provides income support

Business Performance:

• Revenue growth has been steady with Q2 2025 revenue at $8.4B
• Gross margins remain stable around 60%
• ROE of 8.58% shows decent capital efficiency
• Net margin of 15.21% demonstrates solid profitability

Recent Developments:

• Neuroscience division showing accelerated growth with 6.7% revenue increase
• Diabetes segment growing fastest at 11% despite being smallest division
• Strong adoption of new products like AiBLE and Percept

Analyst Views: Recent price targets range from $89-109, with mixed ratings between Hold and Buy. Barclays maintains a bullish outlook with $109 target based on expected accelerating earnings growth in H2 2025.

The stock appears appropriately priced given its steady growth profile, strong market position, and improving business segments, particularly in neuroscience and diabetes. While not significantly undervalued, the current valuation provides a reasonable entry point for long-term investors.

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

Based on the available data and market analysis, here's a projection for Medtronic (MDT) stock price in 2030:

Medtronic's stock is projected to reach approximately $145-155 by 2030, driven by its strong diabetes and neuroscience segments growth, with diabetes revenue growing at 11% and neuroscience at 7% year-over-year. The company's strategic focus on innovative medical technologies and expanding global market presence, particularly in emerging markets, supports this long-term growth trajectory. The company's consistent dividend growth and robust free cash flow yield of nearly 5% provide additional support for this price target.

MDT has a total of 95000 employees.